Provided by Tiger Trade Technology Pte. Ltd.

Nektar Therapeutics

72.89
+0.67000.93%
Volume:466.70K
Turnover:34.21M
Market Cap:2.09B
PE:-7.49
High:74.43
Open:73.00
Low:71.94
Close:72.22
52wk High:77.00
52wk Low:6.48
Shares:28.69M
Float Shares:26.24M
Volume Ratio:0.88
T/O Rate:1.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.7300
EPS(LYR):-8.6765
ROE:-217.94%
ROA:-27.98%
PB:23.28
PE(LYR):-8.40

Loading ...

Nektar Therapeutics Rises on Positive Dermatitis Drug Data

Dow Jones
·
Feb 10

BUZZ-Nektar rises as eczema drug shows year‑long benefit

Reuters
·
Feb 10

New Rezolve-Ad Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements With Both Monthly and Quarterly Dosing

THOMSON REUTERS
·
Feb 10

Nektar Therapeutics kündigt Phase-2b-Studie mit Rezpegaldesleukin bei atopischer Dermatitis an

Reuters
·
Feb 10

Nektar to Hold Conference Call to Discuss Topline Results From the 36-Week Maintenance Period for Its Rezolve-Ad Phase 2B Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026

THOMSON REUTERS
·
Feb 10

Nektar Therapeutics Announces Inducement Stock Option Grant Under 2025 Plan

Reuters
·
Jan 31

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jan 31

Nektar Therapeutics Price Target Maintained With a $118.00/Share by BTIG

Dow Jones
·
Jan 30

Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR) and LivaNova (LIVN)

TIPRANKS
·
Jan 26

Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky Reports Sale of Common Shares

Reuters
·
Jan 23

Septerna appoints Mark Wilson as chief legal officer

TIPRANKS
·
Jan 09

Nektar Therapeutics (NKTR) Stock Slides Despite Analyst Optimism On Alopecia Data

Benzinga
·
Dec 23, 2025

Pliant Therapeutics Appoints Minnie Kuo as Chief Operating Officer

Reuters
·
Dec 17, 2025

Why Nektar Therapeutics (NKTR) Is Down 9.3% After Phase 2b REZOLVE-AA Data Readout And What's Next

Simply Wall St.
·
Dec 17, 2025

HC Wainwright Adjusts Nektar Therapeutics Price Target to $135 From $120, Maintains Buy Rating

MT Newswires Live
·
Dec 17, 2025

Nektar Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 17, 2025

Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion

Benzinga_recent_news
·
Dec 17, 2025

BUZZ-Nektar falls after autoimmune disorder drug misses main goal in mid-stage study

Reuters
·
Dec 16, 2025

Nektar Therapeutics Shares Down 2.4% Premarket After Its Autoimmune Disorder Drug Misses Main Goal in Mid-Stage Study

THOMSON REUTERS
·
Dec 16, 2025

BRIEF-Nektar’s Rezolve-AA Trial Meets Target With 28.2% Salt Drop

Reuters
·
Dec 16, 2025